We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

The fervour of the converted

9 March 2009 By Robert Cyran

The US company has never believed in big pharma M&A. So why is it bidding $44bn for rival ScheringPlough which might lose the right to sell an important drug because of the deal? Well, the two should fit nicely. But the big motivation is $25bnworth of potential cost cuts.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)